


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. St. Joseph Mercy - Oakland</p> <p>2. 44405 Woodward Ave. Pontiac, MI 48341</p>	<p>In accordance with letter dated July 23, 2021,</p>	<p>4. Expiration Date: May 31, 2036</p>
	<p>3. License No.: 21-11651-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-02104 Reference No.:</p>



6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251)	D. 500 millicuries total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. Palladium-103 permitted by 10 CFR 35.400	E. Sealed Sources (Theragenics Corporation, Model TheraSeed 200)	E. 500 millicuries total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-11651-01

Docket or Reference No.:  
030-02104

Amendment No. 68

- |   |   |  |   |
|---|---|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form                        | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use   |
| F. Yttrium-90 permitted by 10 CFR 35.1000             | F. Microspheres (BWXT Medical Ltd., Model TheraSpheres) | F. 3 curies total  | F. For use, as permitted by 10 CFR 35.1000, in a BWXT Medical Ltd. TheraSphere Y-90 Glass Microsphere System. |

**CONDITIONS**

10. Licensed material shall be used or stored at the licensee's facilities located at 44405 Woodward Ave., Pontiac, Michigan, 48341.
11. The Radiation Safety Officer (RSO) for this license is Khurram Rashid, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-11651-01

Docket or Reference No.:

030-02104

Amendment No. 68

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

John Vito Antonucci, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material requiring a written directive), 10 CFR 35.400

Ramin B. Behjatnia, D.O.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Thomas P. Boike, M.D.

10 CFR 35.300; 10 CFR 35.400

James P. Carl, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Daniel J. DeVincent, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Ahmed E. Ezz, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material requiring a written directive), 10 CFR 35.400

Michael Ghilezan, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material requiring a written directive), 10 CFR 35.400

Larry Kestin, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material requiring a written directive), 10 CFR 35.400

Karen Lee Johnson-Haddlesey, M.D.

10 CFR 35.100, 10 CFR 35.200

Alvaro A. Martinez, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material requiring a written directive), 10 CFR 35.400

Kay T. Miller, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material requiring a written directive), 10 CFR 35.400

Nader Mohtadi, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Khurram Rashid, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Stephen Seedial, M.D.

10 CFR 35.1000 (limited to yttrium-90 TheraSpheres)

Frank Vicini, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material requiring a written directive), 10 CFR 35.400

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License No.: 21-11651-01

Docket or Reference No.:  
030-02104

Amendment No. 68

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated January 26, 2021 (ML21027A165)
- B. Letter dated March 29, 2021 (ML21090A159)
- C. Letter dated May 7, 2021 (ML21132A194)
- D. Letter dated July 23, 2021 (ML21232A007)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 24, 2021By: \_\_\_\_\_  
Sara A. Forster  
Region III